Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00888017 · ClinicalTrials.gov registry record
Proton Pump Inhibitor Therapy and Bone Density in Premature Infants
A clinical trial, sponsored by University of Utah.
- Terminated
- Registry status
- 10
- Enrollment target
NCT00888017 is a clinical trial that was terminated before completion, run by University of Utah. The registered enrollment target is 10 participants.
The verdict
NCT00888017 was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- 10 participants
- Enrollment target
Study Summary
Previous research studies have shown that there may be a connection between proton pump inhibitor therapies and hip fracture in adults(1). Proton pump inhibitor(PPI) reflux medications raise the pH of the stomach, which may effect the body's ability to absorb certain calcium compounds. Neonates are at a crucial age for bone mineralization. Because esophageal reflux is common in neonates, PPI therapy is commonly used, despite little information on effectiveness and side effects. PPIs work by blocking the production of protons in the pumps in the stomach, thus making the stomach less acidic. The calcium ion needs an acidic environment in order to be broken down from its natural compounds into an absorbable form (2). This is troubling because of the problems associated with osteopenia in neonates. Bone mineralization is important for premature infants. Rickets and bone fractures are higher in preterm infants than term infants. For this reason, we are investigating whether there is a connection between PPI therapies (specifically Prevacid) and decreased bone densities in neonates. The objective is to determine if a connection exists between proton pump inhibitor antacids and decreased rate of bone mineralization in neonates.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-04 |
| Est. Completion | 2013-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00888017
The ClinicalTrials.gov registry entry for NCT00888017 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00888017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00888017 about?
NCT00888017 is a clinical study titled "Proton Pump Inhibitor Therapy and Bone Density in Premature Infants". Previous research studies have shown that there may be a connection between proton pump inhibitor therapies and hip fracture in adults(1). Proton pump inhibitor(PPI) reflux medications raise the pH of the stomach, which may effect the body's ability to absorb certain calcium compounds. Neonates are...
What is the current status of trial NCT00888017?
This trial is currently terminated. The enrollment target is 10 participants. The study started on 2009-04. Estimated completion is 2013-01.
Who is sponsoring clinical trial NCT00888017?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.